264 320
and has received company speaker honoraria from Pfizer, GSK, Astellas,
and Ipsen. van der Poel is a company consultant for Intuitive Surgical, has
participated in trials for Astellas and Steba Biotech, and has received grant
and research support from Astellas. Rouvie`re is a company consultant for
EDAP-TMS, Bracco, and Philips; has received company speaker honoraria
from EDAP-TMS, Bracco, and Philips; and has participated in trials for
EDAP-TMS and Bracco. Wiegel has received company speaker honoraria
from Astellas, Takeda, Hexal, Ipsen, Janssen-Cilac, and Ferring. Mottet has
received grant and research support from Takeda Pharmaceutical,
Millenium, Astellas, Pierre Fabre, Sanofi, and Pasteur, and has received
honoraria or consultation fees from Takeda Pharaceutical, Millenium,
Jansen, Astellas, BMS, Bayer, Ipsen, Ferring, Novartis, Nucle´tron, Pierre
Fabre, Sanofi, and Zeneca. van den Bergh, Van den Broeck, Cumberbatch,
Fossati, Gross, Henry, van der Kwast, Sylvester, Yuan, Schoots, Moldovan,
and Marconi have nothing to disclose.
Funding/Support and role of the sponsor:
None.
Appendix A. Supplementary data
Supplementary data associated with this article can be
found, in the online version, at
http://dx.doi.org/10.1016/j. eururo.2017.02.026 .References
[1]
Bratan F, Niaf E, Melodelima C, et al. Influence of imaging and histological factors on prostate cancer detection and localisation on multiparametric MRI: a prospective study. Eur Radiol 2013;23:2019–29.[2]
Kim JY, Kim SH, Kim YH, Lee HJ, KimMJ, Choi MS. Low-risk prostate cancer: the accuracy of multiparametric MR imaging for detection. Radiology 2014;271:435–44.[3]
Turkbey B, Pinto PA, Mani H, et al. Prostate cancer: value of multi- parametric MR imaging at 3 T for detection—histopathologic cor- relation. Radiology 2010;255:89–99.[4]
Valerio M, Donaldson I, Emberton M, et al. Detection of clinically significant prostate cancer using magnetic resonance imaging-ul- trasound fusion targeted biopsy: a systematic review. Eur Urol 2015;68:8–19.[5]
Schoots IG, Roobol MJ, Nieboer D, Bangma CH, Steyerberg EW, Hunink MG. Magnetic resonance imaging-targeted biopsy may enhance the diagnostic accuracy of significant prostate cancer detection compared to standard transrectal ultrasound-guided bi- opsy: a systematic review and meta-analysis. Eur Urol 2015;68:438–50.[6]
Wegelin O, van Melick HH, Hooft L, et al. Comparing three different techniques for magnetic resonance imaging-targeted prostate bi- opsies: a systematic review of in-bore versus magnetic resonance imaging-transrectal ultrasound fusion versus cognitive registra- tion. Is there a preferred technique? Eur Urol 2017;71:517–31.[7]
Mottet N, Bellmunt J, Bolla M, et al. EAU-ESTRO-SIOG guidelines on prostate cancer. 2016.[8]
Schoots IG. Omission of systematic transrectal ultrasound guided biopsy from the MRI targeted approach in men with previous negative prostate biopsy might still be premature. Ann Transl Med 2016;4:205.[9]
Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 2009;151:264–9, W64.[10]
Whiting PF, Rutjes AW, Westwood ME, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med 2011;155:529–36.[11]
Barentsz JO, Richenberg J, Clements R, et al. ESUR prostate MR guidelines 2012. Eur Radiol 2012;22:746–57.[12]
Abd-Alazeez M, Ahmed HU, Arya M, et al. The accuracy of multi- parametric MRI in men with negative biopsy and elevated PSA level—can it rule out clinically significant prostate cancer? Urol Oncol 2014;32:45:45.e17–45.e22.
[13]
Abd-Alazeez M, Kirkham A, Ahmed HU, et al. Performance of multiparametric MRI in men at risk of prostate cancer before the first biopsy: a paired validating cohort study using template pros- tate mapping biopsies as the reference standard. Prostate Cancer Prostatic Dis 2014;17:40–6.[14]
Belas O, Klap J, Cornud F, et al. IRMmutiparame´trique de la prostate avant biopsies: la fin des biopsies syste´matise´es? Prog Urol 2012;22:583–9.
[15]
BrockM, von Bodman C, Palisaar J, BeckerW, Martin-Seidel P, Noldus J. Detecting prostate cancer: a prospective comparison of systematic prostate biopsy with targeted biopsy guided by fused MRI and transrectal ultrasound. Dtsch A¨ rztebl Int 2015;112:605–11.
[16]
Busetto GM, De Berardinis E, Sciarra A, et al. Prostate cancer gene 3 and multiparametric magnetic resonance can reduce unnecessary biopsies: decision curve analysis to evaluate predictive models. Urology 2013;82:1355–62.[17]
Cheikh AB, Girouin N, Colombel M, et al. Evaluation of T2-weighted and dynamic contrast-enhanced MRI in localizing prostate cancer before repeat biopsy. Eur Radiol 2009;19:770–8.
[18]
Choi MS, Choi YS, Yoon BI, et al. The clinical value of performing an MRI before prostate biopsy. Korean J Urol 2011;52:572–7.[19]
Cirillo S, Petracchini M, Della Monica P, et al. Value of endorectal MRI and MRS in patients with elevated prostate-specific antigen levels and previous negative biopsies to localize peripheral zone tumours. Clin Radiol 2008;63:871–9.[20]
Ferda J, Kastner J, Hora M, et al. A role of multifactorial evaluation of prostatic 3T MRI in patients with elevated prostatic-specific anti- gen levels: prospective comparison with ultrasound-guided trans- rectal biopsy. Anticancer Res 2013;33:2791–5.
[21]
Ganie F, Wani M, Shaheen F, et al. Endorectal coil MRI and MR- spectroscopic imaging in patients with elevated serum prostate specific antigen with negative TRUS transrectal ultrasound guided biopsy. Urol Ann 2013;5:172–8.
[22]
Grenabo Bergdahl A, Wildera¨ng U, Aus G, et al. Role of magnetic resonance imaging in prostate cancer screening: a pilot study within the Go¨teborg randomised screening trial. Eur Urol 2016;70:566–73.
[23]
Haffner J, Lemaitre L, Puech P, et al. Role of magnetic resonance imaging before initial biopsy: comparison of magnetic resonance imaging-targeted and systematic biopsy for significant prostate cancer detection. BJU Int 2011;108:E171–8.
[24]
Hara N, Okuizumi M, Koike H, Kawaguchi M, Bilim V. Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) is a useful modality for the precise detection and staging of early prostate cancer. Prostate 2005;62:140–7.
[25]
Hauth E, Hohmuth H, Cozub-Poetica C, Bernand S, Beer M, Jaeger H, Multiparametric MRI. of the prostate with three functional tech- niques in patients with PSA elevation before initial TRUS-guided biopsy. Br J Radiol 2015;88:20150422.
[26]
Ibrahiem EI, Mohsen T, Nabeeh AM, Osman Y, Hekal IA, Abou El- Ghar M. DWI-MRI: single, informative, and noninvasive technique for prostate cancer diagnosis. Sci World J 2012;2012:973450.
[27]
Itatani R, Namimoto T, Atsuji S, et al. Negative predictive value of multiparametric MRI for prostate cancer detection: outcome of 5- year follow-up in men with negative findings on initial MRI studies. Eur J Radiol 2014;83:1740–5.
[28]
Iwazawa J, Mitani T, Sassa S, Ohue S. Prostate cancer detection with magnetic resonance imaging: is dynamic contrast-enhancedE U R O P E A N U R O L O G Y 7 2 ( 2 0 1 7 ) 2 5 0 – 2 6 6
264